Protein replacement therapy has strong therapeutic potential, but protein instability, rapid clearance, and poor targeting often limit its effectiveness. Discover how biodegradable lipid nanoparticles and advanced drug delivery systems can protect proteins, improve biodistribution, and enable controlled delivery.
Europe is leading a strategic transition towards personalized and precision medicine, driven by the need to improve outcomes, reduce adverse effects, and increase efficiency in healthcare. In this context, nanomedicine is emerging as a key enabler, offering tools for precise, safe, and scalable delivery of therapeutic [...]
Lipid nanoparticles are transforming rare disease treatment by enabling targeted mRNA and gene therapies. Learn how nanomedicine drives personalized, point-of-care solutions. The rare disease dilemma More than 300 million people worldwide live with a rare disease. Most of them face a long diagnostic journey, limited [...]
The journey from scientific discovery to patient benefit is often long and uncertain. But in recent years, lipid nanoparticles (LNPs) have emerged as a key enabler for accelerating the clinical translation of innovative therapies, including mRNA, proteins, peptides, and gene-editing tools. At DIVERSA, we are designing next-generation nanoparticles that [...]
In recent years, the convergence of protein engineering and nanotechnology has emerged as a transformative force in biomedical science. These two fields, once developed along parallel lines, are now deeply intertwined, offering innovative solutions to some of medicine’s most complex challenges. From improving the stability and functionality of therapeutic [...]
In recent years, lipid nanoparticles (LNPs) and additional types of nanoparticles (from liposomes to polymeric nanoparticles) have played a central role in the transformation of medicine, from enabling groundbreaking mRNA vaccines to delivering genetic therapies for rare diseases and cancer and decreasing toxicity of oncological [...]
